{
    "id": 15101,
    "fullName": "MYC rearrange",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MYC rearrangement indicates an unspecified rearrangement of the MYC gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4609,
        "geneSymbol": "MYC",
        "terms": [
            "MYC",
            "bHLHe39",
            "c-Myc",
            "MRTL",
            "MYCC"
        ]
    },
    "variant": "rearrange",
    "createDate": "12/11/2015",
    "updateDate": "08/28/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19116,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYC rearrangement aids in the diagnosis of adult and pediatric Burkitt lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12369,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MPC-3100 treatment inhibited growth of Burkitt lymphoma cells harboring a MYC rearrangement in culture (PMID: 28619753).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 2772,
                "therapyName": "MPC-3100",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10342,
                    "pubMedId": 28619753,
                    "title": "Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12373,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Buparlisib (BKM120) with PU-H71 resulted in either additive or synergistic effects in Burkitt lymphoma cell lines harboring a MYC rearrangement in culture, and inhibited tumor growth to a greater extent than either agent alone in Burkitt lymphoma cell line xenograft models (PMID: 28619753).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 6475,
                "therapyName": "Buparlisib + PU-H71",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10342,
                    "pubMedId": 28619753,
                    "title": "Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9914,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CUDC-907 inhibited growth of diffuse large B-cell lymphoma (DLBCL) cell lines harboring MYC translocations in culture, and reduced MYC expression and tumor growth in a DLBCL cell line xenograft model harboring a MYC translocation (PMID: 27980108).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 709,
                "therapyName": "CUDC-907",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7758,
                    "pubMedId": 27980108,
                    "title": "Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27980108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12365,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PU-H71 treatment decreased cell viability via induction of cell cycle arrest in Burkitt lymphoma (BL) cell lines harboring a MYC rearrangement, and led to decreased tumor growth in BL cell line xenograft models and a BL patient-derived xenograft (PDX) model (PMID: 28619753).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 1162,
                "therapyName": "PU-H71",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10342,
                    "pubMedId": 28619753,
                    "title": "Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12374,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BEZ235 with PU-H71 resulted in either additive or synergistic effects in Burkitt lymphoma cell lines harboring a MYC rearrangement in culture, and inhibited tumor growth to a greater extent than either agent alone in Burkitt lymphoma cell line xenograft models (PMID: 28619753).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 6476,
                "therapyName": "BEZ235 + PU-H71",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10342,
                    "pubMedId": 28619753,
                    "title": "Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19113,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYC rearrangement aids in the diagnosis of adult and pediatric diffuse large B-cell lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10442,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Alisertib (MLN8237) treatment resulted in partial response lasting 1 month in a patient with B-cell non Hodgkin's lymphoma harboring MYC rearrangement, but the treatment was terminated after 1 cycle due to toxicity (PMID: 28278718).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 60060,
                "name": "non-Hodgkin lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8457,
                    "pubMedId": 28278718,
                    "title": "A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28278718"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 12366,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BIIB021 treatment inhibited growth of Burkitt lymphoma cells harboring a MYC rearrangement in culture (PMID: 28619753).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 2766,
                "therapyName": "BIIB021",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10342,
                    "pubMedId": 28619753,
                    "title": "Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12368,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ganetespib treatment inhibited growth of Burkitt lymphoma cells harboring a MYC rearrangement in culture (PMID: 28619753).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10342,
                    "pubMedId": 28619753,
                    "title": "Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12367,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 0932 treatment inhibited growth of Burkitt lymphoma cells harboring a MYC rearrangement in culture (PMID: 28619753).",
            "molecularProfile": {
                "id": 15360,
                "profileName": "MYC rearrange"
            },
            "therapy": {
                "id": 3588,
                "therapyName": "Debio 0932",
                "synonyms": null
            },
            "indication": {
                "id": 8584,
                "name": "Burkitt lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 10342,
                    "pubMedId": 28619753,
                    "title": "Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28619753"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4865,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment inhibited survival of patient-derived lymphoma cells harboring TP53 inactivating mutation, MYC rearrangement, and RHEB overexpression (PMID: 18708578).",
            "molecularProfile": {
                "id": 19405,
                "profileName": "MYC rearrange RHEB over exp TP53 inact mut"
            },
            "therapy": {
                "id": 3663,
                "therapyName": "Doxorubicin + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4866,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FTI-277 treatment inhibited survival of patient-derived lymphoma cells harboring TP53 inactivating mutation, MYC rearrangement, and RHEB overexpression (PMID: 18708578).",
            "molecularProfile": {
                "id": 19405,
                "profileName": "MYC rearrange RHEB over exp TP53 inact mut"
            },
            "therapy": {
                "id": 1683,
                "therapyName": "FTI-277",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4758,
                    "pubMedId": 18708578,
                    "title": "Tumorigenic activity and therapeutic inhibition of Rheb GTPase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18708578"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15360,
            "profileName": "MYC rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19405,
            "profileName": "MYC rearrange RHEB over exp TP53 inact mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29438,
            "profileName": "MYC rearrange BCL2 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29439,
            "profileName": "MYC rearrange BCL6 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31177,
            "profileName": "MYC rearrange BCL2 rearrange BCL6 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}